News stories about Veru (NASDAQ:VERU) have been trending somewhat positive recently, according to Accern. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Veru earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.1939089470729 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:

Veru (NASDAQ:VERU) opened at $1.24 on Friday. Veru has a fifty-two week low of $0.90 and a fifty-two week high of $3.00.

A number of brokerages recently issued reports on VERU. HC Wainwright set a $5.00 price objective on shares of Veru and gave the company a “buy” rating in a report on Thursday. ValuEngine lowered shares of Veru from a “hold” rating to a “sell” rating in a report on Tuesday, October 31st. Finally, Zacks Investment Research upgraded shares of Veru from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a report on Wednesday, September 27th.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Veru (VERU) Stock Price” was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at

Veru Company Profile

Veru Inc, formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector.

Insider Buying and Selling by Quarter for Veru (NASDAQ:VERU)

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with's FREE daily email newsletter.